Toolgen Incorporated
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Feb 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Platform for Expressing Protein of Interest in Liver (US 11,667,934) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 2 fees due Jun 19 to 30, 2027 · next Jun 19
- 1 fee due Sep 5, 2027The maintenance fee for Method for Identifying DNA Base Editing by Means of Cytosine Deaminase (US 11,920,151) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 3 US 12,781,208 Streptococcus Pyogenes-Derived CAS9 Variant
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,809,839 | Method for concentrating cells that are genetically altered by nucleases In force · USPTO record | In force | USPTO record | |
| US 10,851,380 | Methods for Cleaving a Target DNA Using a Guide RNA Specific for the Target DNA and Cas Protein-Encoding Nucleic Acid or Cas Protein In force · Medium confidence | In force | Medium confidence | |
| US 12,473,559 | Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 12,606,832 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 12,612,632 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 12,612,633 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 12,612,634 | Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells In force · High confidence | In force | High confidence | |
| US 10,519,454 | Genome Editing Using Campylobacter Jejuni CRISPR/Cas System-Derived Rgen In force · High confidence | In force | High confidence | |
| US 12,509,697 | Oleic Acid -Enriched Plant Body Having Genetically Modified FAD2 and Production Method Thereof In force · High confidence | In force | High confidence | |
| US 12,286,635 | Oleic Acid-Enriched Plant Body Having Genetically Modified FAD2 and Production Method Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 27: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
17 pending · 20 abandoned · 4 no status recorded
Rows 11 to 41 of 41 are for members. The first 10 are on the company page.
Pro members see all 41 published applications.